Developing interactions with industry in rare diseases: lessons learned and continuing challenges-Reference-Cited by-同舟云学术

Developing interactions with industry in rare diseases: lessons learned and continuing challenges

Published:2020-01 Issue:1 Volume:22 Page:219-226
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

Berry Susan A.^ORCID,Coughlin Curtis R.^ORCID,McCandless Shawn^ORCID,McCarter Robert^ORCID,Seminara Jennifer,Yudkoff Mark^ORCID,LeMons Cynthia^ORCID

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Genetics (clinical)

Link

http://www.nature.com/articles/s41436-019-0616-9.pdf

Reference29 articles.

1. Shimkus J. H.R.4013–107th Congress (2001–2002): Rare Diseases Actof 2002. 6 November 2002. https://www.congress.gov/bill/107th-congress/house-bill/4013. Accessed 3 October 2017.

2. Wikipedia. National Organization for Rare Disorders. 2017. https://en.wikipedia.org/w/index.php?title=National_Organization_for_Rare_Disorders&oldid=797804566.

3. National Center for Advancing Translational Sciences–Genetic andRare Diseases Information Center. Diseases. https://rarediseases.info.nih.gov/diseases. Accessed 12 April 2019.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation;Journal of Neuromuscular Diseases;2024-01-24

2. Autoimmune polyglandular syndrome of type 1 (hypoparathyroidism, adrenal insufficiency): difficulties in determining the differential and true diagnosis;Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics);2024-01-13

3. Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing;Kidney International;2023-10

4. Together4RD position statement on collaboration between European reference networks and industry;Orphanet Journal of Rare Diseases;2023-09-05

5. Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships;Journal of Inherited Metabolic Disease;2023-04